RESEARCH
Open Access

Short-chain fatty acids can improve lipid and glucose metabolism independently of the pig gut microbiota

Hua Zhou1,2, Bing Yu1,2, Jing Sun3,4, Zuohua Liu3,4, Hong Chen5, Liangpeng Ge3,4*, and Daiwen Chen1,2*

Abstract

Background: Previous studies have shown that exogenous short-chain fatty acids (SCFAs) introduction attenuated the body fat deposition in conventional mice and pigs. However, limited studies have evaluated the effects of exogenously introduced SCFAs on the lipid and glucose metabolism independently of the gut microbiota. This study was to investigate the effects of exogenous introduction of SCFAs on the lipid and glucose metabolism in a germ-free (GF) pig model.

Methods: Twelve hysterectomy-derived newborn pigs were reared in six sterile isolators. All pigs were hand-fed with sterile milk powder for 21 d, then the sterile feed was introduced to pigs for another 21 d. In the second 21-d period, six pigs were orally administrated with 25 mL/kg sterile saline per day and considered as the GF group, while the other six pigs were orally administrated with 25 mL/kg SCFAs mixture (acetic, propionic, and butyric acids, 45, 15, and 11 mmol/L, respectively) per day and regarded as FA group.

Results: Orally administrated with SCFAs tended to increase the adiponectin concentration in serum, enhance the CPT-1 activity in longissimus dorsi, and upregulate the \textit{ANGPTL4} mRNA expression level in colon (\(P<0.10\)). Meanwhile, the mRNA abundances of \textit{ACC}, \textit{FAS}, and \textit{SREBP-1C} in liver and \textit{CD36} in longissimus dorsi of the FA group were decreased (\(P<0.05\)) compared with those in the GF group. Besides, the mRNA expression of \textit{PGC-1a} in liver and \textit{LPL} in longissimus dorsi tended to (\(P<0.10\)) upregulate and downregulate respectively in the FA group. Moreover, oral administration of SCFAs tended to increase the protein level of \textit{GPR43} (\(P<0.10\)) compared with those in the GF group, but the mRNA expression of \textit{PGC-1a} in liver and \textit{LPL} in longissimus dorsi tended to (\(P<0.10\)) upregulate and downregulate respectively in the FA group. Moreover, oral administration of SCFAs tended to increase the protein level of \textit{ACC} (\(P<0.10\)) in liver. Also, oral administration of SCFAs upregulated the \textit{p-AMPK/AMPK} ratio and the mRNA expressions of \textit{GLUT-2} and \textit{GY2S} in liver (\(P<0.05\)). In addition, the metabolic pathway associated with the biosynthesis of unsaturated fatty acids was most significantly promoted (\(P<0.05\)) by oral administration of SCFAs.

Conclusions: Exogenous introduction of SCFAs might attenuate the fat deposition and to some extent improve the glucose control in the pig model, which occurred independently of the gut microbiota.

Keywords: Germ-free, Glucose metabolism, Lipid metabolism, Pig model, Short-chain fatty acids

* Correspondence: geliangpeng1982@163.com; dwchen@sicau.edu.cn
1Key Laboratory of Animal Disease-Resistance Nutrition, Chengdu 611130, Sichuan, China
2Key Laboratory of Pig Industry Sciences, Rongchang 402460, Chongqing, China
Full list of author information is available at the end of the article

© The Author(s). 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Emerging evidence indicated that gut microbiota plays a critical contributor to the host’s health [1]. Noteworthy, the beneficial effects of gut microbiota are at least partly attributed to the short-chain fatty acids (SCFAs), which are the end-products produced from the fermentation of dietary fiber and resistant starch [2, 3]. SCFAs acts as pivotal roles in various biological activities, such as lipid and glucose metabolism [4–6]. Recent studies have reported that oral administration of SCFAs increased the energy expenditure and fat oxidation in obese mice [7], prevented body weight gains, and enhanced insulin sensitivity in high-fat diet-fed mice [8]. Moreover, exogenously introduced SCFAs reduced the fat deposition in weaned and growing pigs by decreasing lipogenesis and promoting lipolysis in different tissues [9, 10]. Human intervention reports found that SCFAs could regulate whole-body substrates and energy metabolism by increasing fasting fat oxidation and resting energy expenditure [11]. However, controversy still exists considering the role of SCFAs in lipid metabolism. Previous work demonstrated that SCFAs were thought to contribute additional calories in the obese, thus resulting in additional weight gain [12]. Conflicting literature indicated that enhanced acetate turnover aggravated the development of obesity and insulin resistance in rodents [13]. The inconsistent effects of SCFAs on lipid and glucose metabolism might affect by gut microbiota, which plays a vital role in the development and progression of obesity [14, 15]. It has been observed that the Christensenella genus could prevent weight gain in mice [16], and the Akkermansia genus was reported to correlate with lower visceral fat deposits [17]. Decreased the abundances of Bacteroides and Prevotella were indicated positively correlated with energy intake and adiposity [18]. Moreover, the numbers of microbiota are closely associated with SCFAs concentrations [19]. Thus, gut microbiota may interfere with the effects of exogenous introduction of SCFAs on the host’s health, and further well-controlled studies are urgently needed. Germ-free (GF) animals are free from living microorganisms, including bacteria, viruses, fungi, protozoa, and parasites throughout their life, and are reared in sterile environments [20, 21]. The pig’s skin, sterile environments, rectal swabs, and oral mucosa were detected via anaerobic (thioglycollate medium) and aerobic (brain heart infusion broth) culture of samples at least every week in accordance with the Chinese National Standard (GB/T 14926-41-2001). Colonized digesta was collected at the end of the experiment for further confirmation of sterile status.

Experimental design and diet
Among the six rearing isolators, three of them were designated as the FA group, and the other three isolators were treated as the GF group. These pigs in the FA and GF groups were hand-fed 60Co-γ-irradiated sterile milk powder (Table S1) and diluted with sterile water 1:4 for 21 d. A corn-soybean feed (Table S2) was formulated according to the requirements of Chinese Feeding Standards (2004) for local pigs. It was sterilized by Co60-γ-radiation and introduced to the GF and FA pigs for another 21 d. In the second 21-d period, the FA group was orally administrated with sterile 25 mL/kg SCFAs mixture (acetic, propionic, and butyric acids, 45, 15, and 11 mmol/L, respectively) per day, and the GF group was orally administrated with 25 mL/kg sterile saline per day. The introduction volume of SCFAs mixture or sterile saline for each pig per day is presented in Table S3. Furthermore, the SCFAs mixture was
confected in the laminar airflow clean benches, and the acetic, propionic, and butyric acids (analytically pure) was filtered through a 0.22-μm membrane and mixing with sterile water. During the two 21-d periods, pigs were allowed ad libitum access to sterile water. To maintain the sterile environment in the present study, when the SCFAs, water, milk, and feed in the rearing isolators were consumed, the replacement containers for sterile SCFAs, water, milk, and feed were delivered into the rearing isolator via the transfer port. Before transferred into the transfer port, the containers were preliminarily decontaminated with 0.5% peracetic acid and then spraying with 1% peracetic acid.

**Sample collections**
In the morning of d 42, blood was drawn from anterior vena cava, centrifuged at 3,000×g for 15 min, and stored at −80°C for further measurements. After bleeding, pigs were euthanized by isoflurane anesthesia. The abdomen was opened in the laminar airflow clean benches, and the samples of the colon, liver, and longissimus dorsi were immediately collected in liquid nitrogen and stored at −80°C for further analysis.

**Serum parameters measurement**
The concentrations of adiponectin, insulin, glucagon, glucagon-like peptide 1, and leptin in serum were detected by commercial enzyme-linked immunosorbent assay (ELISA) kits from Chenglin Co. Ltd. (Beijing, China) in accordance with the manufacturer’s instructions. The levels of total cholesterol (TC), triglyceride (TG), high-density lipoprotein-cholesterol (HDL-c), low-density lipoprotein-cholesterol (LDL-c), and glucose in serum were measured using commercial kits (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) following with the manufacturer’s instructions. Each parameter was simultaneously measured in triplicate on the same plate. The differences among parallels should be small (coefficient of variation was less than 10%) to guarantee the reproducibility of repeated measurements.

**Determination of enzyme activity**
The frozen sample of the liver and longissimus dorsi (approximately 1.0 g) was homogenized in ice-cold saline solution (1:9, wt/vol), centrifuged at 3,000×g for 15 min at 4°C, and stored at −80°C for further analysis. The activities of carnitine palmitoyltransferase 1 (CPT-1), lipoprotein lipase (LPL), hepatic lipase (HL), and malate dehydrogenase (MDH) in liver and longissimus dorsi were determined using commercial kits (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) in accordance with the manufacturer’s instructions. The total protein concentration of liver and longissimus dorsi homogenates was measured by the Bradford brilliant blue method [24]. Each parameter was simultaneously determined in triplicate on the same plate. The differences among parallels should be small (coefficient of variation was less than 10%) to guarantee the reproducibility of repeated measurements.

**Detection of mRNA expression**
Total RNA was isolated from the frozen colon, liver, and longissimus dorsi using Trizol reagent (TaKaRa) in accordance with the manufacturer’s instructions. The purity and concentration of the RNA were detected using a NanoDrop ND-2000 spectrophotometer (NanoDrop, Germany). The OD260/OD280 ratios ranging from 1.8 to 2.0 in all samples were considered as suitable for further measurement. The integrity of RNA was measured by agarose gel electrophoresis, and the 28S:18S ribosomal RNA band ratio was evaluated to be ≥1.8. RNA was reverse transcribed into cDNA by the PrimeScript™ RT reagent kit (TaKaRa) following the manufacturer’s guidelines. Primers for the associated genes (Table S4) were designed via Primer 6 software (PREMIER Biosoft International, Palo Alto, CA, USA) and commercially synthesized by Sangon Biotech Ltd. (Shanghai, China). The quantitative real-time PCR was analyzed on an ABI Prism 7000 detection system in a two-step protocol with SYBR Green (Applied Biosystems, Foster City, CA, USA). Each reaction was contained in a volume of 5 μL SYBR Premix Ex Taq TM (2×), 1 μL cDNA, 0.4 μL of each forward and reverse primer, 0.2 μL ROX reference dye (50×), and 3 μL PCR-grade water. The PCR conditions were the initial denaturation at 95°C for 30 s, followed by 40 cycles of denaturation at 95°C for 10 s, then annealing at 60°C for 25 s, and a 72°C extension step for 5 min. The melting curve was formed following each quantitative real-time PCR determination to verify the specificity of the reactions. β-actin (housekeeping gene) was selected as the reference gene to normalize the mRNA expression of target genes. Gene abundance values of the replicate samples were computed by the 2−ΔΔCT method [25]. The relative abundance of the target genes in the GF group was treat a to be 1.0. Each sample was determined in triplicate.

**Determination of protein levels**
The antibodies against the β-actin, GPR43, p-AMPK, AMPK, CPT-1B, and ACC were brought from Abcam (Cambridge, MA, USA), Cell Signaling Technology (Davers, MA), and Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA), respectively. Protein levels for the β-actin, GPR43, p-AMPK, AMPK, CPT-1B, and ACC in the liver were measured by western blot analysis in accordance with the instructions described by Suryawan et al. [26].
Ultra-high-performance liquid chromatography equipped with quadrupole time of flight mass spectrometry (UHPLC-Q-TOF/MS) analysis

Serum samples were separated by the ultra-high-performance liquid chromatography (UHPLC) system (Agilent 1290, Agilent Technologies, Palo Alto, USA) incorporating a hydrophilic interaction liquid chromatography (HILIC) column (2.1 mm × 100 mm, 1.7 μm; Waters, Milford, MA, USA). The samples were analyzed using a triple time-of-flight (TOF) mass spectrometer (ESI/Triple TOF 5600; AB Sciex, Concord, Canada) equipped with an electrospray ionization source used in positive and negative ion modes. The pretreatment, extraction, and identification of serum samples were according to the procedure described by Hu et al. [27]. The raw data (whiff scan files) were converted into mzXML format using ProteoWizard [28] and were imported to the XCMS software for peak matching, retention time alignment, and peak area extraction [29]. Metabolite structure identification was performed by comparing the accuracy of m/z values (< 25 ppm), and MS/MS spectra were interpreted with an in-house database (Shanghai Applied Protein Technology Co. Ltd., China) established with authentic standards. For the XCMS data, the ion peaks that were missing values greater than 50% in the group were filtered and excluded and data were normalized to total peak intensity. Then, the pattern recognition was analyzed by SIMCA-P software (version 14.1, Umetrics, Umea, Sweden), where could performed to multivariate data measurement, including unsupervised principal component analysis (PCA), supervised partial least squares discriminant analysis (PLS-DA), and supervised orthogonal partial least squares discriminant analysis (OPLS-DA), which were performed to multivariate data measurement, in particular for pattern recognition was analyzed by SIMCA-P software for peak matching, retention time alignment, and peak area extraction [29].

Statistical analysis

Data were analyzed in SAS 9.2 (SAS Institute, Inc., Cary, NC, USA) and analyzed using Student’s t-test, and presented as means ± SEMs. The individual pig was the statistical unit. P < 0.05 was considered to be statistically significant, and tendency was declared with 0.05 < P < 0.10.

Results

There were no differences in growth performance, nutrient digestibility, and relative organs weight between the GF and FA groups [33].

Serum parameters

The impacts of oral administration of SCFAs on the serum parameters are shown in Table 1. Compared with the GF group, the FA group tended to had a higher adiponectin concentration in the serum (P < 0.10).

Activities of enzymes in the liver and longissimus dorsi

The activities of enzymes in the liver and longissimus dorsi are presented in Table 2. The activity of CPT-1 in the longissimus dorsi of the FA group was tended to be higher than that in the GF group (P < 0.10).

Relative mRNA expressions of lipid metabolism-related genes in liver and longissimus dorsi

As shown in Table 3, the mRNA expressions of ANGP TL4 in the colon and PGC-1a in the liver of the FA group tended to upregulate (P < 0.10) compared with those in the GF group. Moreover, the mRNA abundances of ACC, FAS, and SREBP-1C in the liver of the FA group were lower than those in the GF group (P < 0.05). As presented in Table 4, oral administration of SCFAs decreased the mRNA expression of CD36 (P < 0.05).

Table 1: Effects of exogenously introduced SCFAs on the serum parameters in GF pigs.

| Items            | GF          | FA          | P-value |
|------------------|-------------|-------------|---------|
| Adiponectin, μg/L| 74.48 ± 1.62| 80.63 ± 2.32| 0.06    |
| Glucagon, pg/mL  | 28.01 ± 1.52| 30.06 ± 1.23| 0.12    |
| GLP-1, pmol/L    | 2.51 ± 0.06 | 2.57 ± 0.08 | 0.52    |
| Insulin, mIU/L   | 10.20 ± 0.38| 10.76 ± 0.52| 0.40    |
| Leptin, ng/L     | 1403.2 ± 38.30| 1368.4 ± 45.03| 0.57   |
| TC, mmol/L       | 1.45 ± 0.10 | 1.59 ± 0.11 | 0.38    |
| TG, mmol/L       | 0.30 ± 0.03 | 0.50 ± 0.12 | 0.15    |
| HDL, mmol/L      | 0.73 ± 0.08 | 0.80 ± 0.06 | 0.51    |
| LDL, mmol/L      | 0.77 ± 0.05 | 0.81 ± 0.06 | 0.65    |
| Glucose, mmol/L  | 5.31 ± 0.31 | 5.33 ± 0.58 | 0.97    |

GF: germ-free, FA: short-chain fatty acids, GLP-1: Glucagon like peptide 1, TC: total cholesterol, TG: triglyceride, HDL-c: high-density lipoprotein-cholesterol, LDL-c: low-density lipoprotein-cholesterol. Values are means ± SEMs, n = 6/group.
0.05) and tended to downregulate the mRNA expression of LPL (P < 0.10) in the longissimus dorsi.

Relative mRNA expressions of glucose metabolism-related genes in liver and longissimus dorsi

As presented in Table 5, the oral administration of SCFAs upregulated the mRNA expressions of GLU-2 and GYS2 in the liver (P < 0.05). In addition, the mRNA abundances of genes related to glucose metabolism in the longissimus dorsi were no differences between the FA and GF groups (P > 0.10) (Table 6).

The protein level associated with lipid metabolism

As presented in Fig. 1, oral administration of SCFAs tended to increase the protein level of GPR43 (P < 0.10) and tended to decrease the protein level of ACC (P < 0.10), while upregulated the p-AMPK/AMPK ratio (P < 0.05) in the liver.

Metabolomic profile in the serum

To further evaluate the differences in metabolic profiles related to lipid and glucose metabolism between GF and FA groups, UHPLC-QTOF-MS was used to identify the

Table 2 Effects of exogenously introduced SCFAs on the activities associated with lipids metabolism in liver and longissimus dorsi of GF pigs a

| Items                  | GF            | FA            | P-value |
|------------------------|---------------|---------------|---------|
| Liver                  |               |               |         |
| CPT-1, U/mg protein    | 192.40 ± 3.58 | 191.6 ± 7.27  | 0.92    |
| LPL, U/mg protein      | 0.75 ± 0.02   | 0.73 ± 0.10   | 0.86    |
| HL, U/mg protein       | 0.77 ± 0.11   | 0.78 ± 0.06   | 0.97    |
| MDH, U/mg protein      | 43.56 ± 3.93  | 41.62 ± 2.48  | 0.68    |
| Longissimus dorsi      |               |               |         |
| CPT-1, U/mg protein    | 197.70 ± 5.92 | 209.90 ± 1.91 | 0.08    |
| LPL, U/mg protein      | 0.66 ± 0.26   | 0.34 ± 0.05   | 0.28    |
| HL, U/mg protein       | 0.48 ± 0.05   | 0.39 ± 0.04   | 0.21    |
| MDH, U/mg protein      | 4.08 ± 0.32   | 3.41 ± 0.16   | 0.10    |

a GF germ-free, FA short-chain fatty acids, CPT-1 carnitine palmitoyltransferase 1, LPL lipoprotein lipase, HL hepatic lipase, MDH malate dehydrogenase. Values are means ± SEMs, n = 6/group

Table 3 Effects of exogenously introduced SCFAs on the mRNA abundances for key factors associated with lipid metabolism in colon and liver of GF pigs a

| Items                  | GF            | FA            | P-value |
|------------------------|---------------|---------------|---------|
| Colon                  |               |               |         |
| ANGPTL4                | 1.00 ± 0.13   | 1.48 ± 0.17   | 0.06    |
| PPAR-γ                 | 1.00 ± 0.07   | 0.95 ± 0.14   | 0.75    |
| Liver                  |               |               |         |
| ACC                    | 1.00 ± 0.17   | 0.63 ± 0.05   | < 0.01  |
| FAS                    | 1.00 ± 0.16   | 0.56 ± 0.03   | 0.03    |
| CD36                   | 1.00 ± 0.25   | 0.60 ± 0.17   | 0.19    |
| LPL                    | 1.00 ± 0.11   | 0.69 ± 0.13   | 0.11    |
| SREBP-1C               | 1.00 ± 0.09   | 0.72 ± 0.08   | 0.04    |
| PPKAA1                 | 1.00 ± 0.10   | 1.10 ± 0.09   | 0.47    |
| PPKAA2                 | 1.00 ± 0.13   | 0.99 ± 0.08   | 0.95    |
| CPT-1B                 | 1.00 ± 0.14   | 0.98 ± 0.11   | 0.93    |
| PGC-1α                 | 1.00 ± 0.16   | 2.02 ± 0.43   | 0.06    |
| PNPLA2                 | 1.00 ± 0.11   | 0.86 ± 0.15   | 0.47    |

a GF germ-free, FA short-chain fatty acids, ANGPTL4 angiopoietin-like 4, PPAR-γ peroxisome proliferator-activated receptor gamma, ACC acetyl-CoA carboxylase, FAS fatty acid synthase, CD36 fatty acid transporter CD36, LPL lipoprotein lipase, SREBP-1C sterol regulatory element binding protein 1C, PPKAA1 AMP activated alpha 1, PPKAA2 AMP activated alpha 2, CPT-1B carnitine palmitoyltransferase 1B, PGC-1α peroxisome proliferator-activated receptor gamma coactivator-1α, PNPLA2 patatin-like phospholipase domain-containing protein 2. Values are means ± SEMs, n = 6/group

Table 4 Effects of exogenously introduced SCFAs on the mRNA abundances for key factors associated with lipid metabolism in longissimus dorsi of GF pigs a

| Items                  | GF            | FA            | P-value |
|------------------------|---------------|---------------|---------|
| ACC                    | 1.00 ± 0.14   | 0.79 ± 0.03   | 0.19    |
| FAS                    | 1.00 ± 0.33   | 0.68 ± 0.06   | 0.37    |
| CD36                   | 1.00 ± 0.07   | 0.71 ± 0.06   | 0.02    |
| LPL                    | 1.00 ± 0.09   | 0.81 ± 0.04   | 0.08    |
| SREBP-1C               | 1.00 ± 0.18   | 0.65 ± 0.06   | 0.11    |
| PPKAA1                 | 1.00 ± 0.08   | 0.91 ± 0.07   | 0.44    |
| PPKAA2                 | 1.00 ± 0.03   | 1.07 ± 0.06   | 0.39    |
| CPT-1B                 | 1.00 ± 0.15   | 1.14 ± 0.10   | 0.44    |
| PGC-1α                 | 1.00 ± 0.08   | 1.58 ± 0.39   | 0.19    |
| PNPLA2                 | 1.00 ± 0.16   | 0.97 ± 0.14   | 0.90    |

a GF germ-free, FA short-chain fatty acids, ACC acetyl-CoA carboxylase, FAS fatty acid synthase, CD36 fatty acid transporter CD36, LPL lipoprotein lipase, SREBP-1C sterol regulatory element binding protein 1C, PPKAA1 AMP activated alpha 1, PPKAA2 AMP activated alpha 2, CPT-1B carnitine palmitoyltransferase 1B, PGC-1α peroxisome proliferator-activated receptor gamma coactivator-1α, PNPLA2 patatin-like phospholipase domain-containing protein 2. Values are means ± SEMs, n = 6/group

Table 5 Effects of exogenously introduced SCFAs on the mRNA abundances for key factors associated with lipid metabolism in liver of GF pigs a

| Items                  | GF            | FA            | P-value |
|------------------------|---------------|---------------|---------|
| FOXO-1                 | 1.00 ± 0.05   | 1.09 ± 0.04   | 0.22    |
| INSR                   | 1.00 ± 0.06   | 0.81 ± 0.06   | 0.16    |
| INS1                   | 1.00 ± 0.10   | 1.02 ± 0.04   | 0.80    |
| PK3                    | 1.00 ± 0.09   | 0.72 ± 0.02   | 0.12    |
| GLU-2                  | 1.00 ± 0.12   | 0.58 ± 0.08   | < 0.01  |
| PKC1                   | 1.00 ± 0.05   | 1.08 ± 0.01   | 0.14    |
| GSK3                   | 1.00 ± 0.04   | 1.10 ± 0.05   | 0.17    |
| GYS2                   | 1.00 ± 0.01   | 1.67 ± 0.20   | < 0.01  |

a GF germ-free, FA short-chain fatty acids, FOXO-1 forkhead box O1, INSR insulin receptor, IRS1 insulin receptor substrate 1, PK3 phosphatidylinositol 3-kinase catalytic subunit type 3, GLU-2 glucose transporter 2, PKC1 phosphoinositol 3-kinase catalytic subunit type 3, GSK3 glycogen synthase kinase 3, GYS2 glycogen synthase 2. Values are means ± SEMs, n = 6/group
differential metabolites. Serum samples from GF and FA pigs were measured in both positive and negative ionization modes. The PCA, PLS-DA, and OPLS-DA were performed to visualize the LC-MS dataset and exhibit the differences and similarities among the samples. No marked difference between GF and FA groups in PCA analysis (Fig. 2a, b). To further dissect the difference between GF and FA groups, the PLS-DA and OPLS-DA analyses were employed. The PLS-DA (Fig. 2c, d) and OPLS-DA (Fig. 2e, f) score plots show separation between the GF and FA groups in both positive and negative modes. As presented in Fig. 3, the differential metabolites change between GF and FA groups were exhibited by univariate measurement. The red dots exhibit metabolites that differed between GF and FA groups undertaking FC > 1.5 and $P$-value < 0.05. To assess which compounds were responsible for the differences between the two groups, the parameters of VIP > 1.0 and adjusted $P$ < 0.10 were used as key lineages for separating the serum compounds between GF and FA groups (Fig. 4 and Table 7). In total, 33 compounds with a VIP > 1.0 and adjusted $P$ < 0.10 were identified. Among these, 17 metabolites (choline, hypoxanthine, glycerophosphocholine, N1-methyl-2-pyridone-5-carboxamide, L-malic acid, 1-oleoyl-L-alpha-hydroxophosphatic acid, arachidonic acid, stearic acid, ketoisocaproic acid, hypoxanthine, 9R-10S-EpOME, phosphorylcholine, succinate, docosahexaenoic acid, docosatrienoic acid, and palmitic acid) were enriched ($P$ < 0.05) and four metabolites (D-mannose, L-pyroglutamic acid, 4-nitrophenol, and stavudine) were reduced ($P$ < 0.05) in the FA group compared with those in the GF group. Overall, these results suggested that oral administration of SCFAs markedly increased the lipids related compounds (arachidonic acid, stearic acid, docosahexaenoic acid, palmitic acid, glycerophosphocholine), indicating that exogenous SCFAs had a strong impact on the lipid metabolism in pigs. To further understand the physiological difference induced by oral administration of SCFAs, the KEGG pathway database was used to identifying associated metabolic pathways of 33 metabolites detected in serum. According to Fig. 5, these compounds were involved in several biochemical pathways, and the biosynthesis of unsaturated fatty acids pathway was most significantly affected ($P$ < 0.05) by exogenous SCFAs.

**Discussion**

As is known to us, increasing dietary fiber intake contributes greatly to body weight and glucose tolerance [34]. Notably, when introduced with SCFAs, the SCFAs concentrations in the circulation or gut were similar to those observed in a higher fiber diet [35]. Indeed, it has been reported that exogenous introduction of SCFAs attenuated the body fat deposition in both mice, pigs, and humans [7, 10, 11]. Although SCFAs can prevent fat accumulation, while the underlying mechanisms are still

| Items   | GF       | FA       | $P$-value |
|---------|----------|----------|-----------|
| FOXO-1  | 1.00 ± 0.44 | 1.35 ± 0.34 | 0.20      |
| Sirt1   | 1.00 ± 0.02 | 0.86 ± 0.03 | 0.11      |
| INSR    | 1.00 ± 0.09 | 0.99 ± 0.21 | 0.97      |
| INS1    | 1.00 ± 0.15 | 1.08 ± 0.09 | 0.64      |
| PIK3    | 1.00 ± 0.09 | 0.96 ± 0.07 | 0.73      |
| GSK3    | 1.00 ± 0.04 | 1.01 ± 0.08 | 0.91      |

$^a$ GF germin-free, FA short-chain fatty acids, FOX-1 foxo1 forkhead box O1, Sirt1 silent information regulator 1, INSR insulin receptor, IRS1 insulin receptor substrate 1, PIK3 phosphatidylinositol 3-kinase catalytic subunit type 3, GSK3 glycogen synthase kinase 3. Values are means ± SEMs, n = 6/group

**Fig. 1** Effects of exogenously introduced SCFAs on the protein levels of GPR43, p-AMPK, AMPK, CPT-1B, and ACC in the liver of GF pigs. GF, germ-free; FA, short chain fatty acids; ACC, acetyl-CoA carboxylase; CPT-1B, carnitine palmitoyltransferase 1 B; p-AMPK, phosphorylated adenosine monophosphate-activated protein kinase; AMPK, adenosine monophosphate-activated protein kinase; GPR43, G-protein-coupled receptors 43
Fig. 2 (See legend on next page.)
SCFAs can be produced naturally by host metabolic pathways particularly in the liver, but the major site of SCFAs production is the colon which requires the presence of specific bacteria [36]. Moreover, the numbers and diversity of microbiota are positively associated with SCFAs concentrations [19], and several specific microbes species were closely related to host lipid metabolism [16, 17]. However, whether the SCFAs regulate lipid and glucose metabolism independent of the gut microbiota are largely unknown. Therefore, this study was conducted to explore the effects of exogenous introduction of SCFAs on lipid and glucose metabolism in a GF pig model and to further dissect the underlying mechanisms of exogenously introduced SCFAs on the host’s health. To determine the concentration and dose of the SCFAs mixture used in the present experiment, we conducted a preliminary experiment on the conventional Bama piglets \((n = 12)\). In the preliminary trial, when pigs fed with 1.25 S 0 (acetic, propionic, and butyric acids, 75, 25, and 19 mmol/L, respectively) and 25 mL/kg or 1.0 S 0 (acetic, propionic, and butyric acids, 60, 20, and 15 mmol/L, respectively) and 25 mL/kg SCFAs mixture led to diarrhea and death. Meanwhile, the feed intake was not decreased and without diarrhea after 7 d when pigs fed with 0.75 S 0 (acetic, propionic, and butyric acids, 45, 15, and 11 mmol/L, respectively) and 25 mL/kg SCFAs mixture. However, when pigs fed with 0.75 S 0 and 35 mL/kg SCFAs also led to diarrhea and reduced feed intake. Taken together, we determined the mixture concentrations of acetic, propionic, and butyric acids at 45, 15, and 11 mmol/L, respectively, and a dose of 25 mL/kg in the present study.

Acting in peripheral tissues, adiponectin could regulate lipid metabolism and promote energy expenditure [37]. Serum adiponectin concentration was reduced in individuals with obesity and obesity-related diseases [38]. In the present study, oral administration of SCFAs tended to increase the concentration of adiponectin in serum. CPT-1 is the rate-limiting enzyme that determines fatty acids oxidation [39]. ANGPTL4 is a valid inhibitor of lipoprotein lipase to regulate cellular uptake of triglycerides and promote fatty acids oxidation [40, 41]. In our study, oral administration of SCFAs tended to increase the activity of CPT-1 in longissimus dorsi and the mRNA abundance of ANGPTL4 in colon. Meanwhile, we found the mRNA expressions of FAS, ACC, and SREBP-1C in liver of the FA group markedly downregulated compared with those in the GF group. Consistently, previous studies reported similar results in liver, longissimus dorsi, and adipose tissues of conventional pigs [9, 10, 42]. Notably, FAS is the pivotal enzyme that catalyzes fatty acids synthesis [43]. ACC modulates fatty acids metabolism, and its product (e.g. malonyl-CoA) serves as a building block for de novo fatty acids synthesis [44]. The SREBPs increases the transcription of genes that encode the enzymes of fatty acids biosynthesis and cholesterol uptake [45]. In addition, the current study observed the mRNA abundance of CD36 was apparently decreased, and LPL tended to be reduced in longissimus dorsi of the FA group. LPL catalyzes the hydrolysis of

---

**Fig. 2** The PCA, PLS-DA, and OPLS-DA score plots comparing GF (blue rotundities) and FA (green squares) pigs in positive electrospray ionization mode (ESI +) and negative electrospray ionization mode (ESI −) metabolomics profiles of serum. Panels a (ESI +) and b (ESI −) are PCA score plots. Panels c (ESI +, R²X = 0.459, R²Y = 0.096, Q² = 0.649) and d (ESI −, R²X = 0.514, R²Y = 0.099, Q² = 0.818) are PLS-DA score plots. Panels e (ESI +, R²X = 0.317, R²Y = 0.976, Q² = 0.009) and f (ESI −, R²X = 0.307, R²Y = 0.926, Q² = 0.201) are OPLS-DA score plots. GF, germ-free; FA, short chain fatty acids; PCA, principal component analysis; PLS-DA, Partial least squares discriminant; OPLS-DA, orthogonal partial least-squares discriminant.

---

**Fig. 3** Volcano plots showing the distribution of all metabolites based on their fold-change values (X-axis, on a logarithmic scale), P-value (Y-axis, on a logarithmic scale). Panel a is ESI +, Panel b is ESI −, respectively (FC > 1.50 and P-value < 0.05). GF, germ-free; FA, short chain fatty acids.
triglycerides residing in chylomicrons and providing free fatty acids for tissue utilization [39]. CD36, the fatty acids translocase, regulates the uptake of long-chain fatty acids into cells [46], and elevated expression of CD36 in various tissues resulted in lipid overload and lipotoxicity [47]. Noteworthy, the PGC-1α was measured as a vital regulator of fatty acids metabolism [48], and increasing the PGC-1α expression in liver was a negative association with body fat [49]. In the present study, oral administration of SCFAs tended to upregulate the mRNA expression of PGC-1α in liver, in agreement with the previous studies in conventional pigs and mice [7, 10]. Besides, SCFAs have been demonstrated to enhance the rates of oxygen consumption, and to increase both fat oxidation and adaptive thermogenesis in rodents [7, 50]. Collectively, these demonstrated that exogenous SCFAs may decrease the lipid deposition by downregulating the mRNA expressions of genes related to fatty acids synthesis and enhancing energy expenditure in the liver and longissimus dorsi of GF pigs.

The liver also plays a central role in regulating blood glucose homeostasis by uptake of glucose in the postprandial state and conversion to glycogen and triglyceride, and via the production of glucose in the postabsorptive state through glycogenolysis and gluconeogenesis [51, 52]. The rate-limiting enzyme for glycogen synthesis is glycogen synthase (GS), in mammals, there are two GS isoforms: muscle GS (encoded by GYS1) is abundantly expressed in skeletal and cardiac muscles, and the liver-restricted isoform (encoded by GYS2) [53]. Previous work indicated that mice lacked GYS2 had a severe decrease in their ability to store glycogen in hepatocytes [53]. It is well exhibited that insulin resistance and hepatic steatosis lead to compromised glycogen synthesis [54]. On the contrary, an increase in liver glycogen synthesis directly associated with improved glucose tolerance [55]. In the present study, oral administration of SCFAs significantly increased the mRNA expression of GYS2 in the liver. Similarly, it has been shown that SCFAs supplementation reduced adiposity and improved glucose homeostasis compared to the control group [56]. The GLUT-2 transports glucose in the liver to pass the membrane in a bi-directional way for glycolysis and gluconeogenesis and was identified as a major contributor to glucose and fructose homeostasis in the liver [57]. The increase in the expression of GLUT-2 in liver may be associated with insulin resistance and type-2 diabetes mellitus [58]. In the current study, we found that oral administration of SCFAs markedly downregulated the mRNA abundance of GLUT-2 in liver. These suggested that exogenous SCFAs may improve glucose control in the liver of GF pigs.

Although previous scientists had done much work, the underlying mechanisms of SCFAs on lipid and glucose metabolism are still not fully understood. G-protein-coupled receptors (GPRs), GPR41 and GPR43 have been demonstrated to be indispensable for a range of SCFA-mediated effects [59, 60]. SCFAs have been shown to promote energy consumption and fat combustion by activating the GPRs [61]. Meanwhile, it has been indicated that GPR43 knockout mice exhibited a reduction in energy expenditure, while overexpression of GPR43 exhibited an increase in energy expenditure [62]. Moreover, the effects of SCFAs involving improvement of insulin response are also regulated by GPR43, which induces enhanced glucose control [63]. In our study, we observed the protein expression level of GPR43 in liver of the FA group tended to be upregulated compared with that in the GF group. In addition to the SCFAs-GPRs
| Adduct | Metabolites | Metabolic pathway | M-to-Z | Rt, s | VIP | FC | P-value |
|--------|-------------|-------------------|--------|-------|-----|----|--------|
| M+     | Choline     | Glycerophospholipid metabolism | 104.11 | 559.22 | 3.47 | 1.25 | 0.0042 |
| (M + H)+ | Hypoxanthine | Purine metabolism | 137.05 | 349.60 | 6.37 | 1.33 | 0.0058 |
| M+     | Glycerophosphocholine | Glycerophospholipid metabolism | 258.11 | 781.81 | 8.80 | 1.53 | 0.0124 |
| (M + H)+ | N1-Methyl-2-pyridone-5-carboxamide | Nicotinate and nicotinamide metabolism | 153.07 | 127.37 | 1.36 | 1.32 | 0.0212 |
| (M+Na)+ | D-Mannose | Lysosome | 203.05 | 574.98 | 1.70 | 0.65 | 0.0314 |
| (M + H)+ | L-Pyroglutamic acid | Glutathione metabolism | 130.05 | 751.76 | 1.85 | 0.65 | 0.0344 |
| (M + Na)+ | 1-Palmitoyl-sn-glycero-3-phosphocholine | — | 518.32 | 386.60 | 1.49 | 1.24 | 0.0575 |
| (M-H + 2Na)+ | 1-Stearoyl-2-hydroxy-sn-glycero-3-phosphocholine | — | 568.34 | 367.11 | 4.30 | 1.74 | 0.0699 |
| (M + H)+ | 1-Palmitoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine | — | 454.29 | 396.52 | 1.27 | 1.57 | 0.0790 |
| (M + H)+ | 2-Amino-2-methyl-1,3-propanediol | — | 70.06 | 541.31 | 1.15 | 0.78 | 0.0801 |
| (M + H)+ | 2-Hydroxyadenine | Purine metabolism | 152.06 | 457.91 | 1.50 | 1.32 | 0.0813 |
| (M + H)+ | Deoxycytidine | Pyrimidine metabolism | 228.10 | 421.57 | 1.02 | 0.74 | 0.0881 |
| (M-H)- | L-Malic acid | Renal cell carcinoma | 131.01 | 727.91 | 1.80 | 1.85 | 0.0009 |
| (M + Na-2H)+ | 1-Oleoyl-L-alpha-lysophosphatidic acid | — | 457.23 | 438.26 | 1.67 | 1.63 | 0.0027 |
| (M-H)- | 4-Nitrophenol | — | 138.02 | 59.08 | 1.05 | 0.82 | 0.0167 |
| (M-H)- | Stearic acid | Biosynthesis of unsaturated fatty acids | 327.23 | 67.13 | 8.88 | 1.87 | 0.0413 |
| (M-H)- | 2-Hydroxyadenine | — | 117.02 | 67.07 | 1.11 | 1.58 | 0.0170 |
| (M-H)- | Docosatrienoic acid | — | 301.22 | 68.36 | 4.80 | 1.90 | 0.0505 |
| (M-H)- | Palmitic acid | — | 305.25 | 66.69 | 4.36 | 1.67 | 0.0543 |
| (M-H)- | Eicosapentaenoic acid | — | 301.22 | 68.36 | 4.80 | 1.90 | 0.0505 |

*GF* germ-free, FA short chain fatty acids, M-to-Z mass-to-charge ratio, Rt retention time; the VIP value was obtained from OPLS-DA model with a threshold of 1.0; FC fold change, was calculated by dividing the mean intensity of FA group pig’s serum metabolites by the mean intensity of GF group pig’s serum metabolites; the significance P-value was obtained from Student’s test with a threshold of 0.10.
pathway being involved in the regulation of lipid and glucose metabolism, adenosine monophosphate-activated protein kinase (AMPK) also plays an important role in this regulation. Accumulating evidence demonstrated that SCFAs could increase AMPK activity in the liver and muscle [7, 64]. In the present study, the ratio of p-AMPK/AMPK was significantly increased in the FA group. Additionally, SCFAs were found to mediate liver lipid and glucose homeostasis via activating the PPAR-dependent AMPK-ACC pathway, which regulated the effects of SCFAs on gluconeogenesis and lipogenesis [8]. Of note, the present study observed the protein expression level of ACC in liver of the FA group tended to be higher than that in the GF group. These findings indicated that exogenous SCFAs may decrease fat storage and improve glucose control by binding to the GPR43 and activating the AMPK-ACC pathway in GF pigs.

To further understand the underlying mechanisms of SCFAs on lipid and glucose metabolism, metabolomics analysis was introduced in the present study. Metabolomics is a pyramidal tool for exhaustive research of all metabolites comprised in an organism [65], which offers a novel strategy to identify the potential markers and to explore the molecular mechanisms and metabolic pathways response to specific nutritional interventions. Importantly, the serum can be regarded as a metabolic fingerprint that provides visual results of the metabolic differences and reveals the changes in metabolic pathways under various physiological or nutritional conditions [66]. In the present study, PLS-DA and OPLS-DA analyses demonstrated a clear separation of serum metabolites due to oral administration of SCFAs, suggesting marked differences in the metabolic profiles. Indeed, several fatty acids, such as stearic acid, arachidonic acid,
docosahexaenoic acid, and palmitic acid in the FA group apparently increased compared with those in the GF group. Increases in serum fatty acids levels implied that lipid metabolisms have been altered. Taken KEGG pathway analysis, we observed these fatty acids (stearic acid, arachidonic acid, docosahexaenoic acid, palmitic acid) were involved in the biosynthesis of unsaturated fatty acids pathway. Of note, oral administration of SCFAs has the most significant impact on this metabolic pathway. Intake of unsaturated fatty acids, which consist of monounsaturated fatty acids and polyunsaturated fatty acids, has been associated with favorable cardiac diastolic function and body composition in obese patients [67]. Moreover, increasing unsaturated fatty acids in the diet also prevented weight gain and cardiac dysfunction in a mouse model [68]. Consequently, these suggested that exogenous introduction of SCFAs may alleviate the lipid deposition via activating the metabolic pathway of biosynthesis of unsaturated fatty acids in GF pigs.

Conclusions

In summary, this study demonstrated that SCFAs may attenuate fat deposition and to some extent improve glucose control in the liver and longissimus dorsi, which occur independently of the gut microbiota. The possible mechanisms of exogenous SCFAs on lipid reduction and glucose tolerance improvement may be via binding to the GPR43 and activating the AMPK-ACC pathway, and stimulating the metabolic pathway of biosynthesis of unsaturated fatty acids in GF pigs. The current work further suggested the importance of the presence of gut microbes and provided novel evidence that exogenous introduction of SCFAs may be a possible therapeutic strategy to prevent metabolic disorders and to counteract the gut microbiota deficiency or imbalance.

Abbreviations

ACC: Acetyl-CoA carboxylase; AMPK: Adenosine monophosphate-activated protein kinase; ANGPTL4: Angiopoietin-like 4; CD36: Fatty acid transporter; CD636; CPT-1B: Carnitine palmitoyltransferase 1 B; FAS: Fatty acid synthase; FOXO-1: Foxo1 forkhead box O1; GA: Glucose-6-phosphatase; GF: Germ-free; GLU-2: Glucose transporter 2; GPR43: G-protein-coupled receptors 43; GSK3: Glycogen synthase kinase 3; IRS1: Insulin receptor substrate 1; LDL-c: Low density lipoprotein-cholesterol; PPARE: Peroxisome proliferator-activated receptor gamma; PPARα: Peroxisome proliferator-activated receptor gamma; PPARα1: AMP activated alpha 1; PPARα2: AMP activated alpha 2; Sirt1: Silent information regulator 1; SREBP-1C: Sterol regulatory element binding protein 1C; TC: Total cholesterol; TG: Triglyceride; UHPLC-Q-TOF/MS: Ultrahigh-performance liquid chromatography equipped with quadrupole time of-flight mass spectrometry; VIP: Variable importance in the projection.
benefits via gut-brain neural circuits. Cell. 2014;156(1-2):84–96. https://doi.org/10.1016/j.cell.2013.12.016.

6. Sahuri-Arisoylu M, Brody LP, Parkinson JR, Parkes H, Navaratnam N, Miller AD, et al. Reprogramming of hepatic fat accumulation and ‘browning’ of adipose tissue by the short-chain fatty acid acetate. Int J Obes. 2016;40(6):955–63. https://doi.org/10.1038/ijo.2016.32.

7. Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes. 2009;58(7):1509–17. https://doi.org/10.2337/db08-1637.

8. den Besten G, Bleeker A, Gerding A, van Eunen K, Havinga R, van Dijk TH, et al. Short-chain fatty acids protect against high-fat diet-induced obesity via a PPARα-dependent switch from lipogenesis to fat oxidation. Diabetes. 2015;64(7):2398–408. https://doi.org/10.2337/db14-1213.

9. Jiao AR, Diao H, Yu B, He J, Yu J, Zheng P, et al. Oral administration of short-chain fatty acids could attenuate fat deposition of pigs. PLoS One. 2018;13(5):e0196867. https://doi.org/10.1371/journal.pone.0196867.

10. Jiao A, Yu B, He J, Yu J, Zheng P, Luo Y, et al. Short chain fatty acids could prevent fat deposition in pigs via regulating related hormones and genes. Food Funct. 2020;11(2):1945–55. https://doi.org/10.1039/D0FF00258E.

11. Canfora EE, van der Beek CM, Jocken JWE, Goossens GH, Holst JJ, Olde Damink SWM, et al. Colonic infusions of short-chain fatty acid mixtures promote energy metabolism in overweight/obese men: a randomized crossover trial. Sci Rep. 2017;7(1):2350. https://doi.org/10.1038/s41598-017-02546-x.

12. Tumbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027–31. https://doi.org/10.1038/nature05144.

13. Perry RJ, Peng L, Barry NA, Cline GW, Zhang D, Cardone RL, et al. Peroxisome proliferator-activated receptor-alpha (PPAR-α) regulates gene expression in pig small intestine. J Anim Sci. 2014;92(4):1285–97. https://doi.org/10.2527/jas.2013-7560.

14. Meurens FO, Summerfield A, Nauwynck H, Saif L, Gerdts V. The pig: a model agrimedical model for the study of pediatric nutrition and metabolism. Appl Microbiol. 1964;12(4):295–300. https://doi.org/10.1128/AM.12.4.295-300.1964.

15. Delzenne NM, Cani PD. Interaction between obesity and the gut microbiota: relevance in nutrition. Annu Rev Nutr. 2011;31:1–17. https://doi.org/10.1146/annurev.nutr.012809.102539.

16. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Researc. 2001;29:2–10.

17. Suryawans A, Nguyen HV, Bush JA, Davis TA. Developmental changes in the feeding-induced activation of the insulin-signaling pathway in neonatal pigs. Am J Physiol Endocrinol Metab. 2001;281(5):E908–15. https://doi.org/10.1152/ajpendo.2001.281.5.E908.

18. Hu L, Che L, Wu C, Curatsu MV, Wu F, Fang Z. Metabolomic profiling reveals the difference on reproductive performance between high and low lactational weight loss sows. Metabolomics. 2019;5:39.

19. Chambers MC, Maclean B, Burke R, Amoide D, Ruderman DL, Neumann S, et al. A cross-platform toolkit for mass spectrometry and proteomics. Nat Biotechnol. 2012;30(10):918–20. https://doi.org/10.1038/nbt.2377.

20. Maia H, Tiselius G, Tiselius GM, Brant AM, Cederholm T, Eklund AC, et al. A cross-platform metabolomics study of the breast milk of women with and without gestational diabetes. J Proteome Res. 2011;10(2):675–84. https://doi.org/10.1021/jr100232e.

21. Zhao H, Liu Z, Wang S, Cui D, Zhang X, Liu Y, Zhang Y. UHPLC-Q-TOF/MS based plasma metabolomics reveals the metabolic perturbations by manganese exposure in rat models. Metallomics. 2017;9(2):192–203. https://doi.org/10.1039/C6MT00007C.

22. Peng JH, Wu HF, Chen Z. Metabolic responses of Hela cells to silica nanoparticles by NMR-based metabolomic analyses. Metabolomics. 2013;9(4):874–86. https://doi.org/10.1007/s11306-013-0499-8.

23. Deswal E, Zhang G, Dunn SM, Mandal R, Wishart DS, Annet AJ. BC-MS metabolomics identifies metabolite alterations that precede subclinical mastitis in the blood of transition dairy cows. J Proteome Res. 2016;16(2):433–46. https://doi.org/10.1021/acs.jproteome.6b00538.

24. Zhou H, Sun J, Ge L, Liu Z, Chen H, Yu B, Chen D. Exogenous infusion of short-chain fatty acids can improve intestinal functions independently of the gut microbiota. J Anim Sci. 2020;98(12). https://doi.org/10.1093/jas/skaa371.

25. Peta KD, Anne N, Rozata A, Ying SL, Filipe DY, Tulika A, et al. Dietary fiber-induced improvement in glucose metabolism is associated with increased abundance of prevotella. Cell Metab. 2015;22:97–102.

26. Hu L, Che L, Wu C, Curatsu MV, Wu F, Fang Z. Metabolomic profiling reveals the difference on reproductive performance between high and low lactational weight loss sows. Metabolomics. 2019;5:39.

27. Hu L, Che L, Wu C, Curatsu MV, Wu F, Fang Z. Metabolomic profiling reveals the difference on reproductive performance between high and low lactational weight loss sows. Metabolomics. 2019;5:39.

28. Chambers MC, Maclean B, Burke R, Amoide D, Ruderman DL, Neumann S, et al. A cross-platform toolkit for mass spectrometry and proteomics. Nat Biotechnol. 2012;30(10):918–20. https://doi.org/10.1038/nbt.2377.

29. Maia H, Tiselius G, Tiselius GM, Brant AM, Cederholm T, Eklund AC, et al. A cross-platform metabolomics study of the breast milk of women with and without gestational diabetes. J Proteome Res. 2011;10(2):675–84. https://doi.org/10.1021/jr100232e.
